Chronic hepatitis C in the aged: much ado about nothing or nothing to do?

Related Experiment Video

Updated: May 1, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

7.2K

Stephen Malnick1, Yaakov Maor, Ehud Melzer

  • 1Department of Internal Medicine C, Kaplan Medical Center, Affiliated with the Hebrew University of Jerusalem, Rehovot, Israel, stevethemal@icloud.com.

Drugs & Aging
|March 26, 2014
PubMed

Insights

Hepatitis C treatment has advanced, achieving an 80% cure rate with modern therapies. However, evidence for treating older populations, particularly baby boomers, remains limited.

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Geriatric Medicine

Background:

  • Hepatitis C is a prevalent global infection, a leading cause of cirrhosis, liver cancer, and liver transplantation.
  • Recent advancements in antiviral therapies have significantly improved sustained viral response (SVR) rates, approaching 80% for hepatitis C.
  • The majority of individuals with chronic hepatitis C belong to the 'baby boomer' generation (born 1945-1965), who are now aging.

Purpose of the Study:

  • To review the epidemiology of hepatitis C in the aging population.
  • To examine the clinical manifestations of hepatitis C in older adults.
  • To assess current treatment strategies for hepatitis C, considering data specific to the aged population.

Main Methods:

  • Literature review of published studies on hepatitis C epidemiology, clinical presentation, and treatment.
  • Analysis of treatment efficacy and safety data from clinical trials and real-world studies, with a focus on older patients.
  • Evaluation of evidence-based guidelines and their applicability to the aging hepatitis C cohort.

Main Results:

  • Hepatitis C affects a significant portion of the aging population, with unique epidemiological trends.
  • Clinical manifestations in older adults may differ, potentially impacting diagnosis and management.
  • Current hepatitis C treatments, while effective, present complexities regarding comorbidities and drug interactions in the elderly.

Conclusions:

  • There is a critical need for more evidence-based treatment guidelines for hepatitis C in the aging population.
  • Future research should prioritize clinical trials including older participants to address data gaps.
  • Optimizing hepatitis C management in baby boomers requires tailored approaches considering age-related factors.

More Related Videos

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice09:03

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

Published on: February 3, 2012

21.6K
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

6.6K

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
86
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion...
25
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
379
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
382
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to...
42
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
28